Till now, researchers have explored xenogeneic hematopoietic stem cell transplantation [9] and chemotherapy [10, 11] in the treatment of AML patients with DNMT3A R882 mutation. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.